Anne Vest Soerensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anne Vest Soerensen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Anne Kirstine Hundahl Moeller
Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
3 shared publications - Frede Donskov
Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark
3 shared publications Gregers G. Hermann
C Department of Urology , Rigshospitalet, University of Copenhagen , Copenhagen , Denmark
3 shared publications- Gry Assam Taarnhøj
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
3 shared publications - Helle Pappot
Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
3 shared publications - Ida Marie Lind Rasmussen
Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
3 shared publications
Latest Publications
- Open Access
- 19 August 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 192, 113288
Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma
- 19 August 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 192, 113288
Open AccessHealth care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma
- 2 December 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (12) , 1473-1476
Active use of electronic patient-reported outcome in kidney cancer and effect on self-reported physical function: PRORECECA study protocol
- 2 December 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (12) , 1473-1476
Active use of electronic patient-reported outcome in kidney cancer and effect on self-reported physical function: PRORECECA study protocol
- Open Access
- 15 September 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (9) , e36632
Individualizing the Oncological Treatment of Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study
Background: No phase 3 studies have yet been conducted for patients with non–clear cell (CC) renal cell carcinoma (RCC) exclusively due to the rare occurrence of the disease and the heterogenicity in tumor morphology. Consequently, there is no evidence of the optimal treatment, and new approaches are needed. One approach is individualizing treatment based on the gene sequencing of tumor tissue. Additionally, recent studies involving the patient-reported outcomes (PROs) of patients treated for metastatic cancer have shown significant benefits for quality of life, median overall survival, and overall survival. The use of gene sequencing and PROs can be of great importance to patients with rare cancer types, including patients with non-CC RCC, and should be investigated in clinical trials, especially for cases where evidence based on phase 3 studies is difficult to obtain. Objective: We describe the INDIGO study, in which patients, based on gene analyses, will be allocated into 4 treatment arms containing 14 treatments and use electronic PROs. We aim to improve the treatment of patients with non-CC RCC. The end points in the study will be the overall response rate (complete and partial) in the total patient population, which will be based on the RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria, and the time to treatment failure. Methods: INDIGO is a prospective phase 2 trial, and 30 patients will be enrolled. The patients will receive systemic treatment based on genetic analyses of their tumor tissue. All patients will receive electronic questionnaires in a dedicated app—a questionnaire regarding symptoms and side effects and another regarding health-related quality of life. Depending on the treatment regimen, the patients will be seen by a medical doctor every third, fourth, or sixth week, and the effect of the systemic treatment will be evaluated every 6 weeks via a computed tomography scan. The study has been approved by the Danish Medicines Agency and the National Committee on Health Research Ethics (approval number: H-19041833), complies with good clinical practice guidelines, follows the General Data Protection Regulation, and is registered at the Capital Region of Denmark. Results: Recruitment started in March 2020, and at the time of submitting this paper (June 2022), a total of 9 patients have been enrolled. Conclusions: We aim to explore methods for improving the treatment outcomes of patients with non-CC RCC, and the INDIGO study will contribute further data on personalized medicine for rare types of RCC and provide new knowledge on the active use of electronic PROs. Trial Registration: ClinicalTrials.gov NCT04644432, https://clinicaltrials.gov/ct2/show/NCT04644432 ; European Union Drug Regulating Authorities Clinical Trials Database 2019-001316-38, https://tinyurl.com/2p8mb4aw International Registered Report Identifier (IRRID): DERR1-10.2196/36632
- 15 September 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (9) , e36632
Open AccessIndividualizing the Oncological Treatment of Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study
Background: No phase 3 studies have yet been conducted for patients with non–clear cell (CC) renal cell carcinoma (RCC) exclusively due to the rare occurrence of the disease and the heterogenicity in tumor morphology. Consequently, there is no evidence of the optimal treatment, and new approaches are needed. One approach is individualizing treatment based on the gene sequencing of tumor tissue. Additionally, recent studies involving the patient-reported outcomes (PROs) of patients treated for metastatic cancer have shown significant benefits for quality of life, median overall survival, and overall survival. The use of gene sequencing and PROs can be of great importance to patients with rare cancer types, including patients with non-CC RCC, and should be investigated in clinical trials, especially for cases where evidence based on phase 3 studies is difficult to obtain. Objective: We describe the INDIGO study, in which patients, based on gene analyses, will be allocated into 4 treatment arms containing 14 treatments and use electronic PROs. We aim to improve the treatment of patients with non-CC RCC. The end points in the study will be the overall response rate (complete and partial) in the total patient population, which will be based on the RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria, and the time to treatment failure. Methods: INDIGO is a prospective phase 2 trial, and 30 patients will be enrolled. The patients will receive systemic treatment based on genetic analyses of their tumor tissue. All patients will receive electronic questionnaires in a dedicated app—a questionnaire regarding symptoms and side effects and another regarding health-related quality of life. Depending on the treatment regimen, the patients will be seen by a medical doctor every third, fourth, or sixth week, and the effect of the systemic treatment will be evaluated every 6 weeks via a computed tomography scan. The study has been approved by the Danish Medicines Agency and the National Committee on Health Research Ethics (approval number: H-19041833), complies with good clinical practice guidelines, follows the General Data Protection Regulation, and is registered at the Capital Region of Denmark. Results: Recruitment started in March 2020, and at the time of submitting this paper (June 2022), a total of 9 patients have been enrolled. Conclusions: We aim to explore methods for improving the treatment outcomes of patients with non-CC RCC, and the INDIGO study will contribute further data on personalized medicine for rare types of RCC and provide new knowledge on the active use of electronic PROs. Trial Registration: ClinicalTrials.gov NCT04644432, https://clinicaltrials.gov/ct2/show/NCT04644432 ; European Union Drug Regulating Authorities Clinical Trials Database 2019-001316-38, https://tinyurl.com/2p8mb4aw International Registered Report Identifier (IRRID): DERR1-10.2196/36632
- Open Access
- 19 January 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Feasibility of electronic Patient-Reported Outcomes in a complex setting for patients with metastatic non-clear cell renal cell carcinoma: Protocol for the INDIGO basket study (Preprint)
BACKGROUND No phase III studies have yet been conducted for patients with non-clear cell renal cell carcinoma (non-cc RCC) exclusively due to the rare occurrence of the disease and the heterogenicity in tumour morphology. Consequently, there is no evidence of the optimal treatment and new approaches are needed. An active, real-time use of patient-reported outcomes (PRO) is gaining ground in oncology and allows for individualization of care for the patients, which also is warranted in the present population. Recent studies with PRO in patients treated for metastatic cancer have shown a significant benefit in quality of life, median- and overall survival. The use of PRO as endpoint in clinical studies can be of great importance to patients with rare cancer types including patients with non-cc RCC, for whom treatment is highly individualised, and evidence based on phase III studies is difficult to achieve. OBJECTIVE We describe the INDIGO study with focus on active and passive use of electronic patient-reported outcomes (ePRO) in a complex study setting with four different treatment arms containing fourteen treatment options for patients with non-cc RCC. By using new treatments and adding ePRO to the treatment trajectory we aim to improve treatment of the rare subtypes of RCC. METHODS INDIGO is a prospective phase II trial and 30 patients will be enrolled. The patients receive systemic treatment based on genetic analyses of their tumour tissue. All patients will receive two electronic questionnaires: one questionnaire regarding symptoms and side effects is sent weekly and one regarding health-related quality of life is sent every four weeks. The questionnaires are completed in a dedicated electronic app with an interface developed specifically for the INDIGO study. Healthcare professionals daily assess the incoming responses from the patients and can contact the patient to initiate or improve supportive care. In relation to PRO, the study has the following endpoints: Use of PRO tools during treatment both in terms of completion of weekly questionnaires, in terms of possible patterns in the completion in different subgroups of the patients and in terms of following the instructions regarding contact to the hospital. RESULTS The INDIGO study is approved by the Danish Medicines Agency, the National Committee on Health Research Ethics and complies with Good Clinical Practice guidelines, follow General Data Protection Regulation and is registered at the Capital Region of Denmark. Recruitment of patients started in March 2020. CONCLUSIONS We aim to explore methods to improve treatment outcome for patients with non-cc RCC and this feasibility study will demonstrate how ePRO can be implemented in a basket trial by applying active and passive PRO to a phase II treatment study. CLINICALTRIAL ClinicalTrials.gov Identifier: NCT04644432 EudraCT: 2019-001316-38 Danish National Committee on health research ethics: H-19041833
- 19 January 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFeasibility of electronic Patient-Reported Outcomes in a complex setting for patients with metastatic non-clear cell renal cell carcinoma: Protocol for the INDIGO basket study (Preprint)
BACKGROUND No phase III studies have yet been conducted for patients with non-clear cell renal cell carcinoma (non-cc RCC) exclusively due to the rare occurrence of the disease and the heterogenicity in tumour morphology. Consequently, there is no evidence of the optimal treatment and new approaches are needed. An active, real-time use of patient-reported outcomes (PRO) is gaining ground in oncology and allows for individualization of care for the patients, which also is warranted in the present population. Recent studies with PRO in patients treated for metastatic cancer have shown a significant benefit in quality of life, median- and overall survival. The use of PRO as endpoint in clinical studies can be of great importance to patients with rare cancer types including patients with non-cc RCC, for whom treatment is highly individualised, and evidence based on phase III studies is difficult to achieve. OBJECTIVE We describe the INDIGO study with focus on active and passive use of electronic patient-reported outcomes (ePRO) in a complex study setting with four different treatment arms containing fourteen treatment options for patients with non-cc RCC. By using new treatments and adding ePRO to the treatment trajectory we aim to improve treatment of the rare subtypes of RCC. METHODS INDIGO is a prospective phase II trial and 30 patients will be enrolled. The patients receive systemic treatment based on genetic analyses of their tumour tissue. All patients will receive two electronic questionnaires: one questionnaire regarding symptoms and side effects is sent weekly and one regarding health-related quality of life is sent every four weeks. The questionnaires are completed in a dedicated electronic app with an interface developed specifically for the INDIGO study. Healthcare professionals daily assess the incoming responses from the patients and can contact the patient to initiate or improve supportive care. In relation to PRO, the study has the following endpoints: Use of PRO tools during treatment both in terms of completion of weekly questionnaires, in terms of possible patterns in the completion in different subgroups of the patients and in terms of following the instructions regarding contact to the hospital. RESULTS The INDIGO study is approved by the Danish Medicines Agency, the National Committee on Health Research Ethics and complies with Good Clinical Practice guidelines, follow General Data Protection Regulation and is registered at the Capital Region of Denmark. Recruitment of patients started in March 2020. CONCLUSIONS We aim to explore methods to improve treatment outcome for patients with non-cc RCC and this feasibility study will demonstrate how ePRO can be implemented in a basket trial by applying active and passive PRO to a phase II treatment study. CLINICALTRIAL ClinicalTrials.gov Identifier: NCT04644432 EudraCT: 2019-001316-38 Danish National Committee on health research ethics: H-19041833
- Open Access
Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma
Approval of immune checkpoint-inhibitors (ICIs) and BRAF-inhibitors has revolutionized the treatment of metastatic melanoma. Although these drugs have improved overall survival (OS) in clinical trials, real-world evidence for improved long-term survival is still scarce. Clinical data were extracted from the Danish Metastatic Melanoma database. This nation-wide cohort contains data on all patients who received systemic treatment for metastatic melanoma between 2008 and 2016. Ipilimumab, the first approved ICI, was implemented as standard-of-care in Denmark in 2012. Hence, patients were divided in a pre-ICI (2008–2011) and an ICI (2012–2016) era. Patients were defined as long-term survivors if they were alive 3 years after initiation of systemic therapy. Data from 1754 patients were retrieved. Patients treated in the ICI era had an improved median OS (11.3 months, 95% confidence interval (CI) 10.3–12.3) compared with those in the pre-ICI era (median OS 8.3 months, 95% CI 7.4–9.5, p < 0.0001). A higher proportion of long-term survivors was observed in the ICI era (survivors >3 years increased from 13% to 26% and survivors >5 years increased from 9% to 21%; both p < 0.0001). For long-term survivors, known prognostic factors were equally distributed between the two periods, except that long-term survivors in the pre-ICI era were younger. For long-term survivors, 70% were without progression in the ICI era compared with 43% in the pre-ICI era (p < 0.0001). For all patients, the proportion without progression increased from 5% to 18% between the pre-ICI and the ICI era (p < 0.0001), respectively. Implementation of ICI has led to a significant increase in progression-free, long-term survival for real-life patients with metastatic melanoma.
Open AccessImproved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma
Approval of immune checkpoint-inhibitors (ICIs) and BRAF-inhibitors has revolutionized the treatment of metastatic melanoma. Although these drugs have improved overall survival (OS) in clinical trials, real-world evidence for improved long-term survival is still scarce. Clinical data were extracted from the Danish Metastatic Melanoma database. This nation-wide cohort contains data on all patients who received systemic treatment for metastatic melanoma between 2008 and 2016. Ipilimumab, the first approved ICI, was implemented as standard-of-care in Denmark in 2012. Hence, patients were divided in a pre-ICI (2008–2011) and an ICI (2012–2016) era. Patients were defined as long-term survivors if they were alive 3 years after initiation of systemic therapy. Data from 1754 patients were retrieved. Patients treated in the ICI era had an improved median OS (11.3 months, 95% confidence interval (CI) 10.3–12.3) compared with those in the pre-ICI era (median OS 8.3 months, 95% CI 7.4–9.5, p < 0.0001). A higher proportion of long-term survivors was observed in the ICI era (survivors >3 years increased from 13% to 26% and survivors >5 years increased from 9% to 21%; both p < 0.0001). For long-term survivors, known prognostic factors were equally distributed between the two periods, except that long-term survivors in the pre-ICI era were younger. For long-term survivors, 70% were without progression in the ICI era compared with 43% in the pre-ICI era (p < 0.0001). For all patients, the proportion without progression increased from 5% to 18% between the pre-ICI and the ICI era (p < 0.0001), respectively. Implementation of ICI has led to a significant increase in progression-free, long-term survival for real-life patients with metastatic melanoma.
- Open Access
- 8 October 2015
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 55 (3) , 341-348
A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2
Background: Several biomarkers of treatment efficacy have been associated with a better prognosis in patients with metastatic renal cell carcinoma (mRCC). The prognostic significance of biomarkers in the early treatment phase is unclear. Material and methods: In a complete national cohort of mRCC patients receiving first-line tyrosine kinase inhibitors (TKI) or interleukin-2 based immunotherapy (IT) from 2006 to 2010, overall survival (OS) was analysed for baseline International mRCC Database Consortium (IMDC) classification factors and on-treatment time-dependent biomarkers obtained day 1 each cycle week 4–12 after treatment initiation with multivariate analysis and bootstrap validation. Results: A total of 735 patients received first-line TKI (59%) or IT (41%). Median OS was overall 14.0 months and 33.4, 18.5, and 5.8 months for baseline IMDC favourable, intermediate, and poor risk groups, respectively (p < 0.0001). Systolic blood pressure ≥140 mmHg, neutrophils < lower level of normal (LLN), platelets < LLN, sodium ≥ LLN, and LDH ≤1.5 times upper level of normal after treatment initiation were significantly associated with favourable OS independent of baseline IMDC risk group in multivariate analyses stratified for TKI and IT (p ≤ 0.04). Concordance (C)-index for IMDC classification alone was 0.625 (95% CI 0.59–0.66) and combined with the five-factor biomarker profile 0.683 (95% CI 0.64–0.72). For patients with good (3–5 factors) and poor (0–2 factors) biomarker profile median OS were 23.5 and 9.6 months, respectively (p < 0.0001). Adding the five-factor biomarker profile significantly improved prognostication in IMDC intermediate (25.7 vs. 12.0 months, p < 0.0001) and poor (12.8 vs. 6.4 months, p < 0.0001) risk groups. A trend was seen in IMDC favourable risk group (38.9 vs. 28.7 months, p = 0.112). Conclusion: On-treatment hypertension, neutropenia, thrombocytopenia, LDH below 1.5 times upper level of normal, and normal sodium, obtained week 4–12 of treatment, are independent biomarkers of favourable outcome in mRCC, independent of treatment type.
- 8 October 2015
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 55 (3) , 341-348
Open AccessA five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2
Background: Several biomarkers of treatment efficacy have been associated with a better prognosis in patients with metastatic renal cell carcinoma (mRCC). The prognostic significance of biomarkers in the early treatment phase is unclear. Material and methods: In a complete national cohort of mRCC patients receiving first-line tyrosine kinase inhibitors (TKI) or interleukin-2 based immunotherapy (IT) from 2006 to 2010, overall survival (OS) was analysed for baseline International mRCC Database Consortium (IMDC) classification factors and on-treatment time-dependent biomarkers obtained day 1 each cycle week 4–12 after treatment initiation with multivariate analysis and bootstrap validation. Results: A total of 735 patients received first-line TKI (59%) or IT (41%). Median OS was overall 14.0 months and 33.4, 18.5, and 5.8 months for baseline IMDC favourable, intermediate, and poor risk groups, respectively (p < 0.0001). Systolic blood pressure ≥140 mmHg, neutrophils < lower level of normal (LLN), platelets < LLN, sodium ≥ LLN, and LDH ≤1.5 times upper level of normal after treatment initiation were significantly associated with favourable OS independent of baseline IMDC risk group in multivariate analyses stratified for TKI and IT (p ≤ 0.04). Concordance (C)-index for IMDC classification alone was 0.625 (95% CI 0.59–0.66) and combined with the five-factor biomarker profile 0.683 (95% CI 0.64–0.72). For patients with good (3–5 factors) and poor (0–2 factors) biomarker profile median OS were 23.5 and 9.6 months, respectively (p < 0.0001). Adding the five-factor biomarker profile significantly improved prognostication in IMDC intermediate (25.7 vs. 12.0 months, p < 0.0001) and poor (12.8 vs. 6.4 months, p < 0.0001) risk groups. A trend was seen in IMDC favourable risk group (38.9 vs. 28.7 months, p = 0.112). Conclusion: On-treatment hypertension, neutropenia, thrombocytopenia, LDH below 1.5 times upper level of normal, and normal sodium, obtained week 4–12 of treatment, are independent biomarkers of favourable outcome in mRCC, independent of treatment type.
- Open Access
- 1 September 2015
- Published by Elsevier in European Urology
- Vol. 68 (3) , 516-522
Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2
- 1 September 2015
- Published by Elsevier in European Urology
- Vol. 68 (3) , 516-522
Open AccessHealth Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2
- Open Access
- 1 February 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (3) , 553-562
Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2
- 1 February 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (3) , 553-562
Open AccessImproved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2